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History and evolution of Brain 
tumor imaging: Insights through 
Radiology1
This review recounts the history of brain tumor diagnosis 
from antiquity to the present and, indirectly, the history 
of neuroradiology. Imaging of the brain has from the be-
ginning held an enormous interest because of the inherent 
difficulty of this endeavor due to the presence of the skull. 
Because of this, most techniques when newly developed 
have always been used in neuroradiology and, although 
some have proved to be inappropriate for this purpose, 
many were easily incorporated into the specialty. The 
first major advance in modern neuroimaging was contrast 
agent–enhanced computed tomography, which permitted 
accurate anatomic localization of brain tumors and, by vir-
tue of contrast enhancement, malignant ones. The most 
important advances in neuroimaging occurred with the 
development of magnetic resonance imaging and diffusion-
weighted sequences that allowed an indirect estimation 
of tumor cellularity; this was further refined by the de-
velopment of perfusion and permeability mapping. From 
its beginnings with indirect and purely anatomic imaging 
techniques, neuroradiology now uses a combination of an-
atomic and physiologic techniques that will play a critical 
role in biologic tumor imaging and radiologic genomics.
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can aid in patient care
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evidence that these tumors were ever 
treated. The presence of clinically pal-
pable external hyperostosis was used to 
localize the first documented resected 
meningioma (an orbital one) in 1881 in 
Scotland (4). At the same time in Italy 
and London, similar cases were report-
ed. Then in 1895, everything changed.
X-rays and the Brain
In 1895, Wilhelm Roentgen reported 
the discovery of x-rays. Shortly there-
after, the great neurosurgeon, Harvey 
Cushing, stated that x-rays had limited 
utility in the diagnosis of brain tumors 
but that they had value in the diagno-
sis of tumors near the sella turcica (4). 
At about the same time, Fedor Krause, 
a German neurosurgeon used x-rays 
routinely to localize brain tumors and 
wrote a book chapter entirely dedi-
cated to their use for this purpose. In 
1904, an article on the use of x-rays 
to diagnose cerebral infarctions and 
tumors appeared in the Transactions 
of the American Roentgen Ray Soci-
ety; this is probably the first report of 
neuroimaging in an American scientific 
imaging journal (5). Also at that time, 
emulsion-coated glass plates were being 
used by George Pfahler, MD, a radiol-
ogist in the United States, to help diag-
nose brain tumors. Intracranial calcifi-
cations, which can indicate tumors such 
as oligodendroglioma, astrocytoma, 
meningioma, choroid plexus neoplasia, 
and pituitary tumor, are easily seen 
in images in an article by Merrill Sos-
man, MD, that appeared in Radiology 
in 1927 (Fig 1) (6). As seen in another 
article published in 1928 in Radiology, 
cranial nerve VIII schwannomas were 
diagnosed by demonstrating expanded 
internal auditory canals on oblique 
skull radiographs, optic nerve gliomas 
changed the initial ideas. Of course, I 
could have missed some articles or de-
cided not to include some, and for this 
I am solely responsible. I hope that this 
article accurately recounts the history 
of brain tumor imaging and, indirectly, 
of neuroimaging as a specialty.
Diagnosis of Brain Tumors in Antiquity
The oldest medical text, the Edwin 
Smith Papyrus, dates from the 17th 
century bce and describes 48 battlefield 
head and spine injuries but does not 
mention brain tumors (1). Similarly, 
the more recent (albeit also ancient) 
Ebers Papyrus (1500 bce) also does 
not mention brain tumors. In antiquity, 
brain tumors resulted in death and were 
preceded by longstanding symptoms of 
headaches, seizures, and coma. Physi-
cians recognized that these symptoms 
were caused by increased intracranial 
pressure and developed skull trepana-
tion to relieve it. Skull trepanation (or 
trephination) probably originated in 
ancient Africa and South America (2). 
Hippocrates, Socrates, Aulus Cornelius 
Celsus, Galen, and many Byzantine 
physicians do not mention brain tumors 
in their treatises but left clear instruc-
tions regarding trepanation to alleviate 
intracranial pressure.
Since many neurosurgical tech-
niques were perfected at a time of a 
war, it should come as no surprise that 
the Incas, a military state, not only used 
trepanation but were proficient in per-
forming craniotomies with exquisite 
knowledge of anatomy, preserving vital 
structures such as veins and implant-
ing prosthetic materials with relatively 
low rates of infection (3). It seems that 
most Inca surgery was performed for 
trauma, and no documentation of tu-
mor resections exists.
Meningioma plays an important 
role in the history of intracranial tu-
mors, because although other tumors 
disappear as the accompanying brain 
lyses and disintegrates after death, ev-
idence of meningioma remains in an-
cient skulls. Hyperostosis, commonly 
produced by meningioma, has been 
found in Neolithic, Egyptian, and South 
American skulls. However, there is no 
The anniversary of the founding of the Radiological Society of North America offers us the opportunity 
to look at the world of imaging and its 
progress as portrayed by articles ap-
pearing in its preeminent journal, Radi-
ology. For this review, I have chosen to 
approach the history of neuroimaging 
and brain tumor imaging by dividing 
the discipline into “eras.” These eras 
are not strictly defined by chronologies 
but by key imaging advances. For the 
first 50 years and after the development 
and adoption of brain air studies and 
cerebral angiography, only incremental 
progress was seen in neuroradiology. It 
was not until the early 1970s, when pla-
nar imaging matured with the arrival of 
computed tomography (CT), that neu-
roimaging was catapulted into a whirl-
wind of progress with new technologies 
and treatments. 
For this historical vignette, I was 
asked to retell this story on the basis of 
brain tumor imaging since it (together 
with imaging of aneurysms and vascular 
malformations) has been a mainstay of 
neuroradiology throughout the history 
of neuroimaging. All Radiology tables of 
contents for full length articles and case 
reports (which Radiology published in 
the past) were studied, and the articles 
included here are only the ones that ini-
tially described a finding or a technique 
or that resulted in changes to the way 
we practice. Articles based on animal 
studies are not cited here unless they 
are indispensable to understand future 
clinical advances. It is to be noted that 
in Radiology, neuroradiology-related 
articles commonly appear under other 
headings, such as Pediatric Imaging, 
Nuclear Medicine, Experimental Stud-
ies, Ultrasonography (US), and Tech-
nical Developments—not only in the 
Neuroradiology section. The search for 
appropriate articles was not based on 
their citations, because if number of 
citations had been the main criterion, 
important articles that were never cited 
or were cited only a few times might 
have been overlooked. Although a given 
topic may been addressed in a number 
of articles, only the first of such arti-
cles is included, and subsequent ones 
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experience with 34 tumor patients 
and reviewed the literature. Most of 
these tumors were diagnosed by using 
pneumoencephalography.
Across the Atlantic, in Marseilles, 
France, a radiologist (Jean-Athanase 
Sicard) and a rheumatologist (Jacques 
Forestier) had the idea of using positive 
contrast material to outline the spinal 
cord. They injected lipiodol into the 
subarachnoid space, and myelography 
was born. This technique, reported in 
Radiology in 1928 (19), was the first to 
illustrate the concept of “spinal block” 
secondary to lesions that compress the 
spinal cord or expansile cord lesions 
that block the flow of contrast material 
in the subarachnoid space.
At the same time and also in Eu-
rope in 1927, Egas Moniz, a Portuguese 
neurosurgeon intrigued by positive con-
trast agent–enhanced myelography in-
troduced a technique in which sodium 
iodide was directly injected into veins 
first and years later into the carotid 
arteries via a surgical exposure; thus, 
cerebral angiography was created. It 
was not until 1941 that the first report 
of gliomas and praised the diagnos-
tic value of pneumoencephalography. 
In 1936, Radiology published a re-
markable review (12) on gliomas that 
dealt with their diagnosis on the ba-
sis of radiography and air encepha-
lography, which solidified the use of 
these techniques as the most impor-
tant in brain tumor imaging (Fig 2). 
The August 1943 issue of Radiology is 
remarkable because it contains three 
articles about localization of brain 
tumors by using “roentgen methods” 
(13–15). The conclusion of each of the 
articles praised the use of air-contrast 
studies but stressed the need for ade-
quate equipment and rich experience. 
Blockage of the lateral ventricles and 
deformity of the aqueduct of Sylvius 
(cerebral aqueduct) were critical find-
ings for the diagnosis of pineal gland 
tumors on air studies (16). Trapped air 
inside a mass signified cystic degener-
ation and/or necrosis and a high-grade 
malignancy (17). The first Radiology 
article dedicated to imaging of pedi-
atric brain tumors appeared in 1952 
(18). In it, the authors discussed their 
could be inferred by enlargement of the 
optic canals, and cranial nerve tumors 
were suggested by expansion of their 
corresponding outlet foramina (7). 
The location of the normally calcified 
pineal gland also helped in the diag-
nosis of brain tumors. Measurements, 
stereo views, proportional and graphic 
methods of localizing the pineal calcifi-
cation in patients with brain tumors all 
documented gland displacements that 
were abnormal in 30%–50% of cases 
(8). As late as 1949, the only way to 
confirm the diagnosis of a pituitary tu-
mor was careful measurement of the 
sella turcica on radiographs (9).
The Living Brain and Spinal Cord Are 
Visualized
In 1918–1919 at Johns Hopkins Univer-
sity (Baltimore, Md), the neurosurgeon 
Walter E. Dandy, MD, noticed that free 
intraperitoneal air outlined the abdom-
inal organs, and he sought to apply the 
same principle to brain; thus were born 
pneumoencephalography and ventricu-
lography. This was the first technique 
that allowed visualization, albeit indi-
rect, of the living brain, and for this 
development Dandy was nominated for 
the Nobel Prize in 1933. The technique 
was perfected in the early 1940s by an-
other neurosurgeon, Leo M. Davidoff, 
MD, together with the first American 
neuroradiologist, Cornelius G. Dyke, 
MD, at the Neurological Institute of 
New York in New York City. (The first 
article published by Dyke in Radiology 
was “Acquired Subtentorial Pressure 
Diverticulum of a Cerebral Lateral Ven-
tricle.” [Radiology 1942;39:167–174].) 
The first neuroradiology-related ar-
ticle published in Radiology dealt with 
ventriculography in the setting of brain 
tumors (10). Written in 1923, the au-
thors, neurosurgeons from the Mayo 
Clinic (Rochester, Minn), reported on 
532 patients and concluded that air ven-
triculograms were very helpful for diag-
nosing supratentorial masses but were 
not helpful for the diagnosis of small 
and/or cerebellar tumors. A few years 
later, the authors of one article (11) 
showed lateral and midline displace-
ment of the ventricles in the presence 
Figure 1
Figure 1: Radiographic aid in the diagnosis intracranial lesions. 
Radiograph (fig 10 from reference 6) shows a calcified tumor of choroid 
plexus (arrows) in a 27-year-old woman.
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via a femoral approach became a 
relatively risk-free technique. The 
first Radiology article to be entirely 
technique of threading a guidewire 
onto a needle and over it into a cath-
eter; thereafter, cerebral angiography 
on cerebral arteriography was pub-
lished in Radiology (20). This article, 
a case report, reported that the patient 
underwent general anesthesia and the 
common carotid artery was surgically 
exposed and a canula inserted. The an-
giogram was obtained by using Diodrast 
(iodopyracet), a contrast agent previ-
ously used for studies of the kidneys 
and heart and used at a lower concen-
tration for the brain study. The images 
shown in the article demonstrated a 
posterior temporal blush caused by a 
hypervascular glioma.
Precision Neuroradiology, the Swedish 
School, and Their Influence on 
American Neuroradiology
Erik Lysholm (1881–1947) in Stock-
holm, Sweden developed a “skull table” 
apparatus capable of exquisitively dem-
onstrating the anatomy of the skull 
on radiographs. By moving the x-ray 
source spherically while maintaining a 
central spot he created planar tomogra-
phy. An article published in Radiology 
(21) in November 1949 contains several 
tomograms (called “body sections”) and 
illustrated their utility in the diagnosis 
of eighth cranial nerve tumors (this is-
sue of the journal was the first to con-
tain five consecutive neuroradiology-re-
lated articles). Later, Dr Torgny Greitz 
measured the cerebral blood circulation 
time at precisely 4.13 seconds. The first 
article published in Radiology on local-
ization of intracranial tumors by using 
angiography appeared in October 1946 
(22). In the study reported in that ar-
ticle, angiograms in more than 130 pa-
tients with cerebral masses in different 
locations were assessed, and the au-
thors presented beautiful diagrams all 
of major vascular “shifts” that aided in 
localizing these tumors with great pre-
cision. A few months later, the same 
two authors published an article on the 
differential diagnosis of brain tumors 
based on the angiographic patterns of 
the tumors (Fig 3) (23). Precise mea-
surements of the cerebellar arteries al-
lowed for diagnosis of posterior fossa 
tumors (24).
During the same period, Sven-Ivar 
Seldinger (1921–1998) introduced the 
Figure 3
Figure 3: Differential diagnosis of intracranial neoplasms by using cerebral angiography. 
Arteriogram (fig 11A from reference 23) shows temporoparietal glioblastoma with aneurysmal 
dilatations of small vessels.
Figure 2
Figure 2: Pneumoencephalograms (figs 5 [left] and 6 [right] from reference 12) show signs of frontal lobe 
tumor.
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especially with regard to the diagnosis 
of neoplasias.
One of the most famous names 
in medical imaging is that of Sir God-
frey N. Hounsfield, FRS, an engineer 
who, while working at EMI in England, 
created the first CT scanner. In 1971, 
a head-only scanner was installed in 
London, England, and was soon there-
after installed in the United States at 
the Mayo Clinic. A new era of imaging-
based diagnosis began, and many arti-
cles about with CT scanning of brain tu-
mors, intra- and extraaxial hematomas, 
abscesses, and hydrocephalus were 
soon published, forever changing the 
way we examine patients and diagnose 
neurologic disorders. Another impor-
tant event at this time was the introduc-
tion of the first iso-osmolar iodinated 
contrast medium, metrizamide, which 
made myelography safer and routine. 
Soon thereafter, its use was extended 
to CT cisternography which allowed 
diagnosis of cerebrospinal fluid leaks 
easily. In 1975, the first whole-body CT 
units were introduced.
The first article on CT scanning in 
Radiology (January 1974) was written 
by authors from the Massachusetts 
General Hospital (Boston) and shows 
images of an astrocytoma, a metasta-
sis, a meningioma, and a large pituitary 
adenoma; the authors also detailed 
their initial experience with imag-
ing in 273 patients, of whom 62 had 
lesions was about the same). By this 
time, the use of nuclear scanning as 
the first noninvasive method to localize 
brain tumors was already fairly rou-
tine. Seven years later, an article from 
Johns Hopkins University compared 
the results of angiography, pneumo-
encephalography, and scintigraphy in 
the diagnosis of 400 brain lesions and 
found that isotope studies had an accu-
racy of 73% for the diagnosis of tumors 
(31). The lack of discomfort and com-
plications were emphasized and sug-
gested that the technique could serve to 
“screen” patients suspected of harbor-
ing brain tumors. Novel isotopes such 
as mercury 203 (203Hg) were also tried 
and were very successful in identifying 
brain tumors (Fig 4) (32).
Planar Neuroimaging Begins
In the mid-1960s, Kuhl at el (33) re-
ported in Radiology the develop-
ment of the first practical transverse, 
or cross-sectional, isotopic imaging 
method for brain lesions, which re-
sulted in improved visualization of tu-
mors located in the posterior fossa. 
Their report included images of me-
ningiomas and astrocytomas. From the 
early 1940s to 1970, neuroradiology 
experienced only small incremental im-
provements, but in 1971 our ability to 
image the brain changed radically, and 
a new era of neuroimaging commenced, 
dedicated to this technique appeared 
in 1960 (25). In it, the technique was 
used in more than 100 Swedish pa-
tients, 20 of whom had brain tumors, 
and resulted in only one transient 
complication. Radiologists from the 
State University of New York Up-
state Medical Center (Syracuse, NY) 
were the first ones to publish an ar-
ticle in Radiology describing their 
experience with femoral catheter 
neck and cerebral angiography in 
1960 (26). Although this was a rela-
tively small series, no complications 
occurred.
In 1951, Radiology published an 
article (27) that summarized advances 
in cerebral angiography as follows: 
improved contrast media (older ones 
caused blood vessel irritation and dis-
fugurations when extravasated), percu-
taneous arterial access without need to 
surgically expose an artery (although all 
injections were still performed in the 
neck), and serial x-ray changers with 
magazines capable of handling rolls of 
film and faster serial exposures. With 
these advances, precision neuroan-
giography became routine in the Unit-
ed States, even in smaller community 
hospitals (28). In 1959, in an article 
authored by Paul F. J. New, MB, BS, 
FFR (29), cerebral angiography was de-
clared safer, less time consuming, and 
the imaging method of choice when 
brain tumors were suspected.
Early Physiologic Tumor Neuroimaging
In the late 1940s, George E. Moore, 
MD, a surgeon in Minneapolis, Min-
nesota, postulated that some brain 
tumors could selectively take up a ra-
diotracer. He began by injecting fluores-
cein, which outlined tumors at the time 
of surgery, and then tagged the fluores-
cein with radioactive iodine, which al-
lowed visualization of the tumors before 
surgery—an event that began the era of 
brain scanning.
In 1954, the authors of an article 
in Radiology (30) reported the use of 
nuclear scanning in 200 patients and 
concluded that accurate localization 
of brain tumors was possible in 46% 
(the rate of localization of nontumoral 
Figure 4
Figure 4: Brain tumor localization by using 203Hg. Lateral (left) and anteroposterior (right) views (fig 3 from 
reference 32) from brain scan show selective accumulation of 203Hg in left temporal lobe lesion.
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Raymond V. Damadian, MD, reported 
that nuclear magnetic resonance (MR) 
could be used to distinguish normal 
from tumoral tissues and that it would 
play an important future role in the di-
agnosis of cancer. Two years later, Paul 
C. Lauterbur, PhD, reported the first 
images of a mouse obtained with MR 
imaging (46). In England, Peter Man-
sfield, BSc, PhD, FRS, a physicist, de-
veloped the mathematic algorithms that 
allowed rapid imaging and, in 1977, the 
first human MR images were reported 
(47). Lauterbur and Mansfield received 
the Nobel Prize in 2003. In 1984, the 
first two articles (48,49) dealing with 
MR imaging of brain tumors appeared 
in Radiology. In the first report (48), 
T1 measurements of brain masses were 
performed, and the authors found that 
astrocytomas had the longest T1 and 
lipomas had the shortest. The second 
article (49) was a comparison between 
the then well-established CT and MR 
imaging. The authors pointed out that 
very small tumors and calcifications 
were missed at MR imaging (the studies 
were performed with 7-mm-thick sec-
tions and a 0.35-T unit) and that differ-
entiation of tumors from surrounding 
edema was difficult (Fig 7).
The year 1985 saw the publication 
of an article with a focus on pediatric 
brain tumors (50), which established 
the potential of MR imaging in this pa-
tient population. The fact that contrast 
agent administration is essential for 
detection of primary intraaxial tumors 
(Fig 6). In November 1978, the first 
article to show how imaging findings, 
specifically contrast enhancement, cor-
related with astrocytoma grade was 
published in Radiology (39). These au-
thors showed that all high-grade supra-
tentorial tumors (grades 3 and 4) en-
hanced substantially. 
The year 1980 was important, be-
cause the first two pediatric neurora-
diology articles, one on sellar masses 
(40) and the other on brainstem gli-
omas (41), appeared in the same issue 
of Radiology. Even at this time, the ar-
ticle on sellar masses (40) still showed 
skull radiographs and nuclear brain 
scans! But later that year, an article put 
an end to radiographs, angiography, 
and nuclear scans as means of diag-
nosing intracranial tumors (42). In that 
article, CT was shown to be the most 
accurate diagnostic test in over 1000 
patients with brain tumors. This arti-
cle was rapidly followed by two more 
(43,44) proving that CT was also supe-
rior to all other imaging techniques in 
the diagnosis of brain metastases (43) 
and meningiomas (44). One last arti-
cle deserves to be mentioned here. In 
1982, Graeb et al (45) described CT 
changes after tumor treatment that 
simulated recurrence. This is one of the 
earliest descriptions of a phenomenon 
commonly seen in modern brain tumor 
imaging: pseudoprogression.
More or less at the same time that 
CT was evolving, the next revolution in 
neuroimaging was hatching. In 1971 
intracranial tumors (Fig 5) (34). At 
this time, this head imaging–only CT 
scanner produced 13-mm-thick images 
with a matrix of 80 3 80. A second ar-
ticle (35) about CT appeared 5 months 
later, but it dealt with hemorrhage, not 
brain tumors. The January 1975 issue 
of Radiology contained the first article 
(36) entirely dedicated to CT imaging 
of primary and secondary intracranial 
tumors (600 patients), and the au-
thors reported that in 35 patients with 
glioma, only one imaging study was 
false-negative (an optic chiasm glioma) 
and only one was technically subopti-
mal owing to motion. With respect to 
metastases, all CT studies reviewed in 
that article were positive. In September 
1975, an article from Mayo Clinic (37) 
showed brain images that are not too 
different from the ones we obtain to-
day with our radiation dose reduction 
protocols. The authors mention the de-
creasing numbers of air studies, angio-
grams, and nuclear brain scans needed 
to diagnose brain tumors. In that same 
issue of Radiology, the authors of an-
other article (38) detailed the use of 
CT before and after administration of 
contrast material and found that, over-
all, more than 80% of intracranial mass 
lesions showed contrast enhancement 
Figure 6
Figure 6: An approach to contrast enhancement for CT of the brain. 
Transverse scans obtained, A, before and, B, after contrast agent infu-
sion show right thalamic glioblastoma (fig 1 from reference 38).
Figure 5
Figure 5: CT scan obtained with the EMI scanner 
(fig 4 from reference 34). Low-attenuation region 
involving almost the entire left temporal lobe and 
extending into parietal and frontal lobes represents 
astrocytoma.
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of another article (59) concluded that 
dural tails were due to nodular tumor 
seeding and that the surrounding dura 
must be resected (currently, this issue 
is still controversial).
This section would not be com-
plete without a short mention of US. 
Although US was and is commonly used 
to help diagnose brain hemorrhage 
and hydrocephalus, its utility in tumor 
evaluation for both the brain and the 
spinal cord was limited to intraopera-
tive localization. In 1983, Rubin and 
Dohrmann (60) pointed out the utility 
of intraopeative US in depicting small 
(,1-cm) lesions and in helping identify 
cysts and determine the site for biopsy. 
Three years later, results of another 
investigation (61) confirmed that when 
sampled with biopsy, echogenic areas 
seen during intraoperative US provided 
the best sites for tumor grading.
Planar Neuroimaging Matures
The next improvement in CT was 
spiral (or helical) capability, conceived 
by Willi A. Kalender, PhD, a medi-
cal physicist at the University of Wis-
consin–Madison in the 1980s. As the 
articles clearly advocated the use of 
gadolinium chelates to help improve 
tumor identification, as well as iden-
tify target areas for biopsies (55,56). 
In 1990, an article (57) was published 
in which the authors claimed that the 
diagnosis of gliomas on the basis of 
MR imaging findings was similar that 
for histopathologic findings. The rea-
son for this, the authors claimed, was 
that MR imaging allowed evaluation of 
all of the tumor, while histologic exam-
ination was subject to sampling errors.
One of the better known MR im-
aging signs for diagnosing meningi-
oma is the presence of “dural tails.” 
Thickening and contrast enhancement 
of meninges adjacent to the mass 
localize it to the extraaxial compart-
ment and provide clues about its 
nature. However, the authors of one 
article (58) showed that dural tails 
were not due to tumor infiltration 
but rather to reactive changes caused 
by the neighboring tumor. Thus, the 
authors concluded that resection of 
all of enhancing dura at the time of 
surgery was not needed. It is to be 
noted that this opinion was contro-
versial. Later that year, the authors 
but not for delineation of primary 
larger extraaxial masses was noted in 
later in 1985 (51). Not surprisingly, 
this article (51) came from Europe, 
where the contrast agent gadopen-
tetate dimeglumine (then known by its 
chemical name gadolinium–diethylene-
triaminepentaacetic acid, or Gd-DTPA) 
was used for many years before it 
was approved for use in the United 
States. Two years later, Russell et al 
(52) showed that contrast agent ad-
ministration was essential to depiction 
of intracerebral metastases, especially 
those smaller 10 mm in diameter 
and without accompanying cerebral 
edema. This was also the case for ex-
traaxial leptomeningeal metastases for 
which unenhanced MR imaging proved 
to be inferior to contrast-enhanced 
CT (the reader should remember that 
fluid-attenuated inversion-recovery, 
or FLAIR, imaging had not yet been 
developed) (53). Because MR imaging 
allows better characterization of blood 
products than does CT, an article in 
1987 pointed out that complex and 
atypical bleeds tended to be caused 
by underlying primary and secondary 
brain tumors (54). By 1988, several 
Figure 7
Figure 7: MR imaging versus CT in a 10-year-old boy with anaplastic astrocytoma (fig 1 from reference 49). Transverse (a) CT and (b, c) MR images show 
compression of left ventricle and displacement of midline due to compression by a mass. No focal lesion is visible on a, but b (repetition time msec/echo time msec, 
2000/28) and c (2000/56) clearly show mass extending into frontal and parietal white matter (arrows).
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(directional) and that the direction of 
white matter tracts relative to the ori-
entation of the diffusion gradient could 
be mapped. Again, it was LeBihan 
and his group (66) who showed that 
diffusion-tensor imaging (DTI) could 
produce maps that show white matter 
fiber direction. In 1991, the first trac-
tographic images of white matter ap-
peared (66). DTI is useful in displaying 
the normal anatomy of white matter 
tracts for surgical planning and in eval-
uating traumatic injuries, tumors, white 
matter disorders, and some dementias 
and provides physiologic information 
regarding the integrity of brain tissues. 
With respect to brain tumors, DTI is 
helpful in assessing the integrity of the 
white matter around the tumor. Au-
thors of one article (67) reported that 
DTI enables one to distinguish tumor-
infiltrated edema from simply vasogenic 
edema and thus allowed differentiation 
of gliomas from metastases. Authors of 
another article published the same year 
in Radiology (68) also stated that frac-
tional anisotropy (a measurement found 
in DTI studies) aided in detection of tu-
moral infiltration of surrounding tissues 
that is not visible on conventional MR 
images. In a follow-up article (69) by a 
different group of authors, peritumoral 
DTI differences were found in low-and 
high-grade gliomas. A recent refine-
ment of DWI is diffusion kurtosis imag-
ing, which provides information on the 
nonlinear, Gaussian, and non-Gaussian 
components of three-dimensional water 
motion in the brain. When diffusion 
kurtosis imaging was applied to tumors, 
it was found to be better than DWI for 
helping separate glioma grades (70).
Although the foundations of blood 
perfusion imaging were reported in 
1980 by Leon Axel, MD, PhD, from the 
University of California, San Francis-
co, its neuroimaging applications co-
incided with the development of spiral 
CT and MR echo-planar imaging capa-
bilities (71). By using dynamic sequen-
tial imaging, both MR imaging and CT 
can be used to measure the amount 
of contrast agent traveling through 
blood vessels contained in predeter-
mined voxels. This technique is ca-
pable of producing parametric maps 
echo-planar imaging, DWI became the 
first technique to offer fast, practical, 
reliable, reproducible, and easy to inter-
pret physiologic imaging. The first arti-
cle published in Radiology on this topic 
was a report on brain DWI performed 
in cats, which laid the foundation for 
understanding the appearance of the 
normal human brain at DWI (63). Soon 
DWI became, and remains, the imaging 
method of choice for patients suspected 
of having cerebral infarction or abscess 
and is also very helpful in grading brain 
tumors. It is now well known that hy-
percellular tumors such as glioblastoma 
and lymphoma have a lower apparent 
diffusion coefficient (ADC) than do be-
nign masses and that lymphomas show 
a lower ADC than do gliomas (64). Guo 
et al (64) also showed that tumor cellu-
larity is the main determinant of ADC 
(Fig 8).
Advanced Physiologic Tumor 
Neuroimaging
In 1993, Michael E. Moseley, MD (65), 
reported that water diffusion (move-
ment) in white matter was anisotropic 
patient moved through the spiral CT 
machine, the x-ray source described 
a helical trajectory while an array of 
detectors measured the transmission 
through the patient. The first 16-sec-
tion scanner was introduced 2001, and 
a 64-section scanner became available 
in 2004. With respect to brain tumor 
imaging, the greatest advantage of this 
technique is speed, which allows crea-
tion even of CT angiograms and acquisi-
tion of time-dependent blood perfusion 
measurements. Although CT had lost 
some of its luster in the 1980s, spiral 
capabilities reaffirmed its importance 
in neurovascular imaging, particulary in 
the stroke patient, and also helped in 
the diagnosis of brain tumors.
Although MR imaging continued to 
improve, it remained an anatomic imag-
ing method until the clinical deployment 
of diffusion-weighted imaging (DWI). 
The first images from DWI were pre-
sented by Denis LeBihan, MD, PhD, 
at the 1985 RSNA Annual Meeting and 
were later published in Radiology (62). 
Although originally conceived for liver 
imaging, DWI soon found considerable 
utility in neuroimaging. Coupled with 
Figure 8
Figure 8: MR imaging demonstration of glioblastoma multiforme in a 70-year-old man (fig 2a [a] and 2c  
[b] from reference 64). (a) Transverse gadolinium-enhanced T1-weighted MR image (500/11) shows ring-
enhancing mass in left temporal lobe (arrow). (b) Apparent diffusion coefficient map from DWI (b = 1000 
sec/mm2) at same level as a shows high signal intensity in solid posterior portion of tumor (arrow). 1 = 
region of interest for apparent diffusion coefficient calculation.
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characterized with phosphorous 31 MR 
spectroscopy in only 4.5 minutes. A sec-
ond challenge to human MR spectros-
copy is that when measuring water pro-
tons the normal abundant quantity of 
water may obscure other metabolites. 
Later in 1986, an article (79) was pub-
lished in which the authors described a 
technique to reduce the intensity of the 
water peak and allow visualization of 
metabolites such as N-acetylaspartate, 
choline, creatine, and others. This ar-
ticle marked the beginning of clinical 
brain MR spectroscopy as a technique 
that was easy to implement and the re-
sults of which were easy to interpret. 
Three years later, another group of 
investigators (80) clearly showed spec-
tral differences between astrocytoma, 
meningioma (absence of N-acetylas-
partate, a neuronal marker in meningi-
oma), metastases, and cysts. The utility 
of MR spectroscopy in treated brain 
perfusion and is capable of helping 
differentiate low-grade from high-
grade gliomas.
Although we radiologists are ac-
customed to analyzing images, certain 
techniques used in neuroimaging—es-
pecially metabolic ones—use no im-
ages. Most neurospectroscopy exami-
nations have been performed by using 
water protons, although experiences 
in using phosphorus, carbon, nitrogen, 
sodium, and other elements have also 
been reported. Spectroscopy was first 
used by chemists and physicists to ana-
lyze small molecules. A challenge with 
human spectroscopy is the need for 
high uniformity of the magnetic field 
in relatively large MR units for imaging 
humans. 
The first article on MR spectroscopy 
to appear in Radiology (78) detailed ex-
periments with a 1.4-T whole-body unit 
in which samples of human brain were 
that include relative measurements of 
cerebral blood flow and volume and 
mean transit time, as well as time to 
peak enhancement. The first article 
published in Radiology that addressed 
dynamic contrast-enhanced perfusion 
imaging appeared in 1990 (72). Of 12 
patients, six had brain tumors, and all 
masses showed increased perfusion. 
These findings were later refined in 
two articles (73,74). In the first (73), 
it was shown that low-grade gliomas 
had lower perfusion than did glio-
blastomas, while the benign but hy-
pervascular hemangioblastomas had 
the highest perfusion. In the second 
article (74), high cerebral blood vol-
ume in tumors correlated with mitotic 
activity and vascularity but not with 
cellular atypia, endothelial prolifera-
tion, cellularity, or necrosis (Fig 9). 
Nevertheless, this latter article hinted 
at the importance of advanced imag-
ing techniques—that is, the ability of 
such techniques to provide informa-
tion about processes, both histologic 
and physiologic, at cellular levels. 
It known that about 5%–10% of 
glioblastomas arise from malignant 
transformation of lower-grade gliomas, 
and in this respect perfusion imag-
ing was reported to be helpful. In an 
article published in 2008 (75), signifi-
cantly increased perfusion was noted 
12 months before the appearance of 
contrast enhancement in transform-
ing gliomas. Authors of another similar 
article (76) reported that gliomas with 
high perfusion progressed rapidly and 
showed marked reduction in prognosis 
and survival. 
The above-mentioned perfusion 
articles used gadolinium bolus–based 
techniques, however, and in 2003 Ra-
diology published an article (77) in 
which a new technique was reported 
that did not require administration of 
contrast material: arterial spin label-
ing perfusion imaging. In this tech-
nique, an inversion pulse is used to 
label cephalad flowing blood spins, 
which then provides a quantitative 
map of cerebral blood flow. The au-
thors of this initial article reported 
that arterial spin labeling is suitable 
for measurement of microvascular 
Figure 9
Figure 9: Perfusion MR imaging (fig 6 from reference 73). On 
proton density–weighted (top left [2000/30]) and T2-weighted (top right 
[2000/80]) MR images, tumor in right thalamus appears homogeneous 
and enhances only slightly on contrast-enhanced MR image (bottom left). 
Cerebral blood volume map (bottom right) shows varying areas of ele-
vated blood volume in tumor, however, consistent with high-grade glioma.
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metabolites. One of these is taurine, 
the presence of which, particularly in 
pediatric brain tumors, is indicative 
of primitive neuroectodermal tumors 
(87). Another important metabolite is 
myo-inositol which is a glial marker, 
and its presence offers a glimpse into 
the difficulty of treating glioblastoma. In 
one article, myo-inositol and glutamine 
levels were elevated in the normal-
appearing cerebral hemisphere con-
tralateral to a glioblastoma, which is 
consistent with astrocytosis and implies 
diffuse tumoral infiltration at the time 
of diagnosis (88).
Although early radionuclide brain 
tumor imaging was previously dis-
cussed, the next advance in nuclear 
medicine imaging, PET, was estab-
lished by the ability to detect positron-
emitting radionuclides, with three-di-
mensional images displayed similar to 
CT images. PET was first implemented 
in 1961 (the first PET unit was named 
the “head shrinker”) (89). Some years 
tumors was published in Radiology 
(85). In that article, MR spectroscopy 
was reported to help arrive at correct 
clinical management decisions in most 
brain tumor patients. Although it seems 
today that its utility has been well es-
tablished, MR spectroscopy is still con-
sidered an experimental technique by 
most health insurance companies, and 
few will reimburse for it.
Another common problem in clinical 
neuroradiology is attempting to establish 
the origin of a solitary mass. In 2002, 
Radiology published an article in which 
MR spectrosocopy together with perfu-
sion measurements of the peritumoral 
regions (outside the areas of contrast 
enhancement) together enabled differ-
entiation of primary tumor from solitary 
metastasis (86). Metastases, which are 
well defined and often encapsulated, 
showed no elevation of choline or perfu-
sion in their peritumoral regions.
Refinements in MR spectroscopy al-
low for identification of other important 
tumors was outlined in yet another (81) 
article 3 years later (Fig 10). These au-
thors found that treatment-induced ne-
crosis shows a lower choline level than 
do viable tumors, that lactate is more 
common in high-grade tumors, and that 
a progressive decrease in choline dur-
ing treatment correlates with clinical 
improvement. Similarly, posttreatment 
reductions of choline and lactate were 
also observed in brain lymphomas (82). 
Several years later, MR spectros-
copy performed at 3.0 T was also judged 
excellent at enabling distinction of re-
current glioma from radiation effects 
(83). In addition, when dealing with 
peripherally enhancing and centrally 
necrotic cerebral masses, MR spectros-
copy was shown to enable differentia-
tion of abscesses from tumors by virtue 
of demonstrating the presence of amino 
acids that are byproducts of bacterial 
metabolism (84). One year later, an ar-
ticle about the clinical influence of MR 
spectroscopy on the evaluation of brain 
Figure 10
Figure 10: Imaging and spectroscopy in 56-year-old 
woman suspected of having low-grade glioma (fig 2 
from reference 81). (a) Transverse T1-weighted (left) 
and gadolinium-enhanced (right) MR images (600/16) 
show hypointense nonenhancing mass in right 
temporal lobe and insula. (b) Mass is hyperintense on 
gradient-recalled-echo MR image (600/30, 10° flip 
angle). (c) Fluorine 18 fluorodeoxyglucose positron 
emission tomographic (PET) image shows decreased 
glucose metabolism in right insula. (d) Proton MR 
spectroscopic imaging maps for choline, creatine, and 
N-acetylaspartate (NAA). Gray-blue = low metabolite 
signal, yellow-red-white = high metabolite signal.
NEURORADIOLOGY: History and Evolution of Brain Tumor Imaging Castillo
Radiology: Volume 273: Number 2 (Suppl)—November 2014 n radiology.rsna.org S121
performing neurosurgery with MR im-
aging guidance beginning in the early 
1990s, the exact site of biopsy and the 
extent of resection could be determined 
immediately and changed as needed. In 
1999, an article (96) describing the use 
of this technique in 200 patients was 
published. The authors concluded that 
the technique was safe and did not af-
fect the incidence of complications nor 
increase the duration of surgery. Au-
thors of another article (97) reported 
that assessing the clinical importance of 
contrast enhancement in the intraopera-
tive tumor bed was challenging and that 
the correct diagnosis of residual tumor 
could be made in only 80% of patients.
treatments in patients with brain tu-
mors by identifying language and motor 
areas (Fig 11).
Neuroradiology Goes to the Operating 
Room
Postoperative MR imaging studies had 
traditionally been obtained within the 
first 24 hours after surgery to assess 
for the presence of residual tumor af-
ter resection. The rationale behind this 
approach was the thought that most 
contrast enhancement seen before 24 
hours was probably tumor and not re-
active inflammation. We now know that 
this is not true. With the possibility of 
later, Radiology published an article 
(90) in which fluorodeoxyglucose utili-
zation was found to be as reliable as 
histologic findings for predicting type, 
behavior, and recurrence of intracra-
nial meningiomas. Fluorodeoxyglucose 
has some inherent problems, such as 
low specificity and low contrast in brain 
tumors due to the already high uptake 
by the normal brain. Because of this, an 
article published in 1995 (91) reported 
on the use of the novel tracer carbon 11 
tyrosine. Uptake of this amino acid per-
mitted visualization of protein synthesis 
rates in brain tumors, and its sensitivity 
and specificity for their detection were 
very high. This tracer also holds prom-
ise for assessing the effect of therapy 
on brain tumors. Conversely, methi-
onine PET was proved to be a better 
radiotracer for determining the extent, 
rather than the grade, of tumors (92). 
I have previously mentioned that MR 
spectroscopy demonstrates elevated 
choline metabolism in brain tumors. 
Similarly, choline can be labeled with 
18F, and one study (93) showed that the 
use of this PET technique could help 
differentiate among high-grade gliomas, 
metastases, and benign lesions.
Whereas functional MR imaging is 
not a technique that is directly used to 
evaluate the substance of brain tumors, 
it plays an important role in the eval-
uation of tumor resectability. With its 
ability to demonstrate changes in blood 
oxygenation induced by increased ac-
tivity in the cerebral cortex, functional 
MR imaging is capable of mapping 
some motor and sensory activities. In 
patients whose tumors are closely asso-
ciated with eloquent brain regions (ie, 
motor cortex, language areas), func-
tional MR imaging may help establish 
their locations and, thus, resection po-
tential. In this regard, the first pertinent 
functional MR imaging article appeared 
in Radiology in 1999 (94). The authors 
of this article evaluated lesions around 
the central sulcus, and functional maps 
showed expected or deformed activa-
tions that were thought to be helpful 
in surgical planning. Research results 
(95) from Duke University (Durham, 
NC) showed that functional MR imag-
ing enables more aggressive surgical 
Figure 11
Figure 11:  Preoperative functional MR imaging localization of language and motor areas in a 37-year-old 
woman with recurrent left parietal anaplastic astrocytoma (fig 2 from reference 95). T2-weighted echo-planar 
MR images (2000/40) displayed as threshold activation maps (red and yellow) overlaid on T2-weighted fast 
spin-echo images (3000/84). Green arrows = dominant receptive speech areas, yellow arrows = dominant 
expressive speech areas.
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divided into four molecular subtypes, 
and it is interesting to note that in 
one study (100) the proneural-expres-
sive type showed lower enhancement, 
whereas the mesenchymal-expressive 
type showed more enhancement; 
in addition larger glioblastomas 
harbored epidermal growth factor re-
ceptor mutations, whereas smaller 
ones showed TP53 mutations. Early 
data from animal studies (101) also 
showed that specific nanoparticles that 
found that incompletely and completely 
enhancing glioblastomas showed dif-
ferences in gene expressions and that 
patients with incompletely enhancing 
tumors had longer survival (98). In a 
different study (99), contrast-enhanc-
ing regions in glioblastomas were found 
to overexpress genes that were involved 
with up-regulation of mitosis, angio-
genesis, and apoptosis, all of which 
contribute to aggressive behavior of 
tumor (Fig 12). Glioblastomas can be 
Genetics and High-Field-Strength MR 
Imaging of Brain Tumors
Some of the most exciting advances in 
our understanding of brain tumors have 
come from the wealth of genetic infor-
mation that has recently become avail-
able, and, not surprisingly, neuroradi-
ologists are working on finding imaging 
surrogates for many genetic markers. In 
2008, a group of investigators from the 
University of California, Los Angeles, 
Figure 12
Figure 12: Relationship between contrast enhancement and genetic expression pattern of glioblastoma multiforme (fig 2 from reference 99).  
Left: Genetic expression map of biopsy samples (Bx) with hierarchical clustering of the 500 most-variant genes. Blue = gliosis (G) samples, 
green = enhancing samples, purple = nonenhancing samples. Right: Spoiled gradient-recalled acquisition in the steady state MR image. Green 
circle = enhancing region for biopsy, purple circle = nonenhancing region for biopsy.
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bind to neovascular elements and were 
labeled with gadolinium may allow vi-
sualization of brain tumor vascularity 
and thus allow identification of those 
tumors that may benefit from antian-
giogenic therapies.
High-field-strength MR imaging 
may also prove useful for imaging 
brain tumors. Using gradient-echo 
sequences at 8 T, Christoforidis et al 
(102) were able to identify tumoral 
microvascularity previously only seen 
at microscopy—a finding that corre-
lates with tumor grade. A recent ar-
ticle (103) detailed the benefits of the 
integration of MR imaging, messen-
ger RNA expression, and DNA copy 
number variations.
Conclusion
From this review, it is clear to me 
that neuroradiology has progressively 
moved from a strictly anatomy-based 
discipline to one that combines anat-
omy and physiology. As early as the 
1940s, physiologic parameters such 
as those seen in cerebral angiography 
started to play an important role in the 
diagnosis of neurologic diseases, espe-
cially tumors. A true move toward phys-
iologic imaging did not occur until the 
clinical implementation of MR imaging. 
Although most efforts to find imaging 
expressions of cellular, biologic, and ge-
netic markers are being accomplished 
with MR imaging, it is my belief that 
our current techniques are still too few 
and primitive to allow us to use MR im-
aging as the only means of identifying 
and quantifying these processes. Yet, 
there is no doubt in my mind that these 
answers will be solved in the years to 
come and that many of these advances 
will appear in Radiology first.
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